Study identifier:D4320C00041
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Open-label, Single-arm Study to Determine the Single and Multiple Dose Pharmacokinetics of 10mg ZD4054 (Zibotentan) Administered Once Daily in Male, Elderly Chinese Patients with Advanced Solid Malignancies
Advanced solid malignancies
Phase 1
No
ZD4054 (Zibotentan)
Male
15
Interventional
50 Years +
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to assess the pharmacokinetics of single and multiple doses of 10mg ZD4054 (Zibotentan) in male, elderly Chinese patients with advanced solid malignancies.
Location
Location
Shanghai, Shanghai, China
Arms | Assigned Interventions |
---|---|
Experimental: 1 ZD4054 (Zibotentan) 10mg | Drug: ZD4054 (Zibotentan) 10 mg ZD4054 (Zibotentan) once daily on Day1, Day4 to Day15 Other Name: Zibotentan |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.